Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 3,258,628 shares changed hands during mid-day trading, an increase of 238% from the previous session's volume of 962,819 shares.The stock last traded at $8.00 and had previously closed at $8.21.
Analyst Ratings Changes
A number of research analysts recently commented on RGLS shares. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Friday, March 14th. Leerink Partners restated a "market perform" rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Jones Trading reaffirmed a "hold" rating and set a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Leerink Partnrs downgraded shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Finally, Wall Street Zen began coverage on shares of Regulus Therapeutics in a research note on Sunday, May 18th. They set a "sell" rating for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Regulus Therapeutics presently has a consensus rating of "Hold" and an average target price of $8.50.
View Our Latest Report on Regulus Therapeutics
Regulus Therapeutics Trading Down 3.8%
The firm's fifty day moving average is $6.53 and its 200 day moving average is $3.18. The company has a market cap of $546.88 million, a PE ratio of -10.81 and a beta of 0.35.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. As a group, sell-side analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.
Insider Transactions at Regulus Therapeutics
In other news, insider Preston Klassen bought 12,000 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was purchased at an average price of $7.99 per share, for a total transaction of $95,880.00. Following the completion of the purchase, the insider now owns 48,055 shares in the company, valued at approximately $383,959.45. This trade represents a 33.28% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.35% of the company's stock.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Federated Hermes Inc. lifted its stake in Regulus Therapeutics by 23.1% in the first quarter. Federated Hermes Inc. now owns 15,819,863 shares of the biopharmaceutical company's stock valued at $27,685,000 after buying an additional 2,967,209 shares during the last quarter. Baker BROS. Advisors LP purchased a new position in Regulus Therapeutics during the 1st quarter worth $4,715,000. Driehaus Capital Management LLC purchased a new position in Regulus Therapeutics during the 1st quarter worth $1,677,000. Millennium Management LLC increased its stake in Regulus Therapeutics by 69.7% in the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after purchasing an additional 900,743 shares during the period. Finally, Octagon Capital Advisors LP raised its holdings in shares of Regulus Therapeutics by 13.7% in the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock valued at $7,661,000 after buying an additional 585,101 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.
Regulus Therapeutics Company Profile
(
Get Free Report)
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
